Efficacy and safety of SB-728-T in patients with HIV/AIDS.
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Jan 2017
Price : $35 *
At a glance
- Drugs SB 728 T (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- 06 Jan 2017 According to a Sangamo Therapeutics media release, this trial was originally conducted by Sangamo BioSciences but later on this company's name changed to Sangamo Therapeutics.
- 21 May 2014 New trial record